|
1
|
Tian Y, Xu L, Li X, Li H and Zhao M:
SMARCA4: Current status and future perspectives in non-small-cell
lung cancer. Cancer Lett. 554:2160222023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Witkowski L, Nichols KE, Jongmans M, van
Engelen N, de Krijger RR, Herrera-Mullar J, Tytgat L, Bahrami A,
Mar Fan H, Davidson AL, et al: Germline pathogenic SMARCA4 variants
in neuroblastoma. J Med Genet. 60:987–992. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qiu Z and Ghosh A: A calcium-dependent
switch in a CREST-BRG1 complex regulates activity-dependent gene
expression. Neuron. 60:775–787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang T, Peng B, Luo T, Tian D, Zhao Z, Fu
Z and Li Q: ZEB1 recruits BRG1 to regulate airway remodelling
epithelial-to-mesenchymal transition in asthma. Exp Physiol.
107:515–526. 2022. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katayama Y, Iwasaki T, Yamamoto T, Shimada
N, Nakashima M, Toya M, Narutomi F, Tomonaga T, Kato K and Oda Y:
Loss of SMARCA4 induces sarcomatogenesis through
epithelial-mesenchymal transition in ovarian carcinosarcoma. Cancer
Sci. 116:835–845. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duplaquet L, So K, Ying AW, Pal Choudhuri
S, Li X, Xu GD, Li Y, Qiu X, Li R, Singh S, et al: Mammalian
SWI/SNF complex activity regulates POU2F3 and constitutes a
targetable dependency in small cell lung cancer. Cancer Cell.
42:1352–1369.e13. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pang LL, Zhou HQ, Zhang YX, Zhuang WT,
Pang F, Chen LJ, Liao J, Huang YH, Mao TQ, Mai ZH, et al: SWI/SNF
family mutations in advanced NSCLC: genetic characteristics and
immune checkpoint inhibitors' therapeutic implication. ESMO Open.
9:1034722024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malone HA and Roberts CWM: Chromatin
remodellers as therapeutic targets. Nat Rev Drug Discov.
23:661–681. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Radko-Juettner S, Yue H, Myers JA, Carter
RD, Robertson AN, Mittal P, Zhu Z, Hansen BS, Donovan KA, Hunkeler
M, et al: Targeting DCAF5 suppresses SMARCB1-mutant cancer by
stabilizing SWI/SNF. Nature. 629:E122024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jang JY, Seo JH, Choi JJ, Ryu HJ, Yun H,
Ha DM and Yang J: Insight into microbial extracellular vesicles as
key communication materials and their clinical implications for
lung cancer (Review). Int J Mol Med. 56:1192025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Q, Zhang Z, Wang Y, Peng X, Fang Y,
Zhang Y, Chen L, Huang T, Yang Z, Li C, et al: ARID1A Mediates
SWI/SNF-independent maintenance of heterochromatin architecture to
restrain viral mimicry and immunogenicity in colon cancer. Cancer
Res 2026. (Epub ahead of print).
|
|
12
|
Shi M, Pang L, Zhou H, Mo S, Sheng J,
Zhang Y, Liu J, Sun D, Gong L, Wang J, et al: Rare
SMARCA4-deficient thoracic tumor: Insights into molecular
characterization and optimal therapeutics methods. Lung Cancer.
192:1078182024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiu X, You L, Wang C and Sheng J: Non
small cell lung cancer with SMARCA4 deficiency harboring rare EGFR
mutations exhibited significant tumor response when treated with
afatinib: A case report. Front Med. 19:170–173. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yavas A, Ozcan K, Adsay NV, Balci S,
Tarcan ZC, Hechtman JF, Luchini C, Scarpa A, Lawlor RT, Mafficini
A, et al: SWI/SNF complex-deficient undifferentiated carcinoma of
the pancreas: Clinicopathologic and genomic analysis. Mod Pathol.
37:1005852024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zane LK, Yee LM, Chang TC, Sklar J, Yang
G, Wen JD, Li P, Harrington R, Sims DJ, Harper K, et al: A
concordance study among 26 NGS laboratories participating in the
NCI molecular analysis for therapy choice clinical trial. Clin
Cancer Res. 31:3512–3525. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hötzel KJ, Havnar CA, Ngu HV, Rost S, Liu
SD, Rangell LK and Peale FV: Synthetic Antigen Gels as Practical
Controls for Standardized and Quantitative Immunohistochemistry. J
Histochem Cytochem. 67:309–334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Longo V, Catino A, Montrone M, Montagna
ES, Pesola F, Marech I, Pizzutilo P, Nardone A, Perrone A, Gesualdo
M and Galetta D: Treatment of thoracic SMARCA4-deficient
undifferentiated tumors: Where we are and where we will go. Int J
Mol Sci. 25:32372024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miyazaki N, Ibusuki A, Higashi Y,
Yoshizaki A, Miyauchi I, Sakaguchi I, Kitazono I, Egawa G and
Kanekura T: Thoracic SMARCA4-deficient undifferentiated tumor
diagnosed from a rapidly enlarging cutaneous metastasis. J
Dermatol. 53:e238–e239. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng Q, Lakra P, Gou P, Yang H, Meydan C,
Teater M, Chin C, Zhang W, Dinh T, Hussein U, et al: SMARCA4 is a
haploinsufficient B cell lymphoma tumor suppressor that fine-tunes
centrocyte cell fate decisions. Cancer Cell. 42:605–622.e11. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei XW, Lu C, Zhang YC, Fan X, Xu CR, Chen
ZH, Wang F, Yang XR, Deng JY, Yang MY, et al: Redoxhigh phenotype
mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes
tissue-resident memory CD8+ T cells and attenuates the efficacy of
immunotherapy in lung adenocarcinoma. Oncoimmunology.
13:23401542024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Giglio A, De Biase D, Favorito V,
Maloberti T, Di Federico A, Zacchini F, Venturi G, Parisi C,
Gustavo Dall'Olio F, Ricciotti I, et al: STK11 mutations correlate
with poor prognosis for advanced NSCLC treated with first-line
immunotherapy or chemo-immunotherapy according to KRAS, TP53,
KEAP1, and SMARCA4 status. Lung Cancer. 199:1080582025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Pandey S, Travers M, Sun H,
Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA,
et al: Targeting CDK9 reactivates epigenetically silenced genes in
cancer. Cell. 175:1244–1258.e26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alessi JV, Elkrief A, Ricciuti B, Wang X,
Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi
CAM, et al: Clinicopathologic and genomic factors impacting
efficacy of first-line chemoimmunotherapy in advanced NSCLC. J
Thorac Oncol. 18:731–743. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nambirajan A, Singh V, Bhardwaj N, Mittal
S, Kumar S and Jain D: SMARCA4/BRG1-deficient non-small cell lung
carcinomas: A case series and review of the literature. Arch Pathol
Lab Med. 145:90–98. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawachi H, Kunimasa K, Kukita Y, Nakamura
H, Honma K, Kawamura T, Inoue T, Tamiya M, Kuhara H, Nishino K, et
al: Atezolizumab with bevacizumab, paclitaxel and carboplatin was
effective for patients with SMARCA4-deficient thoracic sarcoma.
Immunotherapy. 13:799–806. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun F, Zou B, Li H, Xu C, Luo Q, Wang C,
Xu P, Pei D, Chen J, Qin D, et al: Structural basis for
BCL7B-mediated ncBAF-nucleosome engagement. Nucleic Acids Res.
54:gkag0922026. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Li H, Li X, Cui H, Li R, Zhu J, Cui
H, Liu Y and Cheng Y: Clinicopathological characteristics and
therapeutic outcomes in patients with non-small cell lung cancer
harboring SMARCA4 mutations. Ann Med. 58:26202012026. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rami-Porta R, Nishimura KK, Giroux DJ,
Detterbeck F, Cardillo G, Edwards JG, Fong KM, Giuliani M, Huang J,
Kernstine KH Sr, et al: The International Association for the Study
of Lung Cancer lung cancer staging project: Proposals for revision
of the TNM stage groups in the forthcoming (Ninth) Edition of the
TNM classification for lung cancer. J Thorac Oncol. 19:1007–1027.
2024. View Article : Google Scholar : PubMed/NCBI
|
